, Tracking Stock Market Picks
Enter Symbol:

up 70.97 %

MEDIVATION INC (MDVN) rated Buy by Goldman

Posted on: Tuesday,  May 7, 2013  8:25 AM ET by Goldman

Goldman rated Buy MEDIVATION INC (NASDAQ: MDVN) on 05/07/2013, when the stock price was $53.85. Since
then, MEDIVATION INC has gained 70.97% as of 01/27/2016's recent price of $92.07.
If you would have followed this Goldman's recommendation on MDVN, you would have gained 70.97% of your investment in 995 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/7/2013 8:25 AM Buy
as of 12/13/2013
1 Week up  1.51 %
1 Month up  0.57 %
3 Months up  5.69 %
1 YTD up  17.25 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy